Onconetix Statistics
Total Valuation
Onconetix has a market cap or net worth of $4.40 million. The enterprise value is $14.17 million.
Important Dates
The last earnings date was Tuesday, December 10, 2024, before market open.
| Earnings Date | Dec 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Onconetix has 8.29 million shares outstanding. The number of shares has increased by 76.69% in one year.
| Current Share Class | 8.29M |
| Shares Outstanding | 8.29M |
| Shares Change (YoY) | +76.69% |
| Shares Change (QoQ) | +135.38% |
| Owned by Insiders (%) | 11.45% |
| Owned by Institutions (%) | 7.54% |
| Float | 3.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.21 |
| Forward PS | n/a |
| PB Ratio | 0.13 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06, with a Debt / Equity ratio of 0.25.
| Current Ratio | 0.06 |
| Quick Ratio | 0.03 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.20 |
Financial Efficiency
Return on equity (ROE) is -201.34% and return on invested capital (ROIC) is -23.14%.
| Return on Equity (ROE) | -201.34% |
| Return on Assets (ROA) | -19.14% |
| Return on Capital (ROIC) | -23.14% |
| Revenue Per Employee | $155,884 |
| Profits Per Employee | -$4.30M |
| Employee Count | 12 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 3.38 |
Taxes
| Income Tax | -139,776 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.36% in the last 52 weeks. The beta is 3.19, so Onconetix's price volatility has been higher than the market average.
| Beta (5Y) | 3.19 |
| 52-Week Price Change | -92.36% |
| 50-Day Moving Average | 0.88 |
| 200-Day Moving Average | 4.42 |
| Relative Strength Index (RSI) | 41.58 |
| Average Volume (20 Days) | 17,210,225 |
Short Selling Information
The latest short interest is 266,626, so 3.21% of the outstanding shares have been sold short.
| Short Interest | 266,626 |
| Short Previous Month | 57,335 |
| Short % of Shares Out | 3.21% |
| Short % of Float | 7.63% |
| Short Ratio (days to cover) | 0.45 |
Income Statement
In the last 12 months, Onconetix had revenue of $1.87 million and -$51.60 million in losses. Loss per share was -$71.24.
| Revenue | 1.87M |
| Gross Profit | -732,035 |
| Operating Income | -13.75M |
| Pretax Income | -45.82M |
| Net Income | -51.60M |
| EBITDA | -13.10M |
| EBIT | -13.75M |
| Loss Per Share | -$71.24 |
Full Income StatementBalance Sheet
The company has $341,495 in cash and $10.12 million in debt, giving a net cash position of -$9.78 million or -$1.18 per share.
| Cash & Cash Equivalents | 341,495 |
| Total Debt | 10.12M |
| Net Cash | -9.78M |
| Net Cash Per Share | -$1.18 |
| Equity (Book Value) | 41.02M |
| Book Value Per Share | 4.08 |
| Working Capital | -16.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.89 million and capital expenditures -$24,597, giving a free cash flow of -$13.91 million.
| Operating Cash Flow | -13.89M |
| Capital Expenditures | -24,597 |
| Free Cash Flow | -13.91M |
| FCF Per Share | -$1.68 |
Full Cash Flow StatementMargins
| Gross Margin | -39.13% |
| Operating Margin | -735.24% |
| Pretax Margin | -2,766.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |